APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Klebsiella Pneumoniae Infection Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Klebsiella Pneumoniae Infection Drug Market Outlook and Growth Opportunities 2026

Report ID 174005960422 December 2025203 pages

Choose your research edition.

Industry ResearchKlebsiella Pneumoniae Infection Drug Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Klebsiella Pneumoniae Infection Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Klebsiella Pneumoniae Infection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Klebsiella Pneumoniae Infection Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Klebsiella Pneumoniae Infection Drug Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Klebsiella Pneumoniae Infection Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Klebsiella Pneumoniae Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Klebsiella Pneumoniae Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Klebsiella Pneumoniae Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Klebsiella Pneumoniae Infection Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Klebsiella Pneumoniae Infection Drug market include Acies Bio doo, Appili Therapeutics, Debiopharm International SA, Evaxion Biotech ApS, FOB Synthesis Inc, ImmunoClin Corp, Innovation Pharmaceuticals Inc, Kyorin Pharmaceutical Co Ltd and Melinta Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Klebsiella Pneumoniae Infection Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Klebsiella Pneumoniae Infection Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Klebsiella Pneumoniae Infection Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Klebsiella Pneumoniae Infection Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Klebsiella Pneumoniae Infection Drug Segment by Company

Acies Bio doo

Appili Therapeutics

Debiopharm International SA

Evaxion Biotech ApS

FOB Synthesis Inc

ImmunoClin Corp

Innovation Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Nosopharm SAS

Peptilogics Inc

Phico Therapeutics Ltd

Sarepta Therapeutics Inc

Shionogi & Co Ltd

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Pfizer Inc

F. Hoffmann-La Roche Ltd

Klebsiella Pneumoniae Infection Drug Segment by Type

ATI-1503

CA-824

CC-1807

Cefiderocol

Debio-1454

EBX-004

Others

Klebsiella Pneumoniae Infection Drug Segment by Application

Hospital

Clinic

Others

Klebsiella Pneumoniae Infection Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Klebsiella Pneumoniae Infection Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Klebsiella Pneumoniae Infection Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Klebsiella Pneumoniae Infection Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Klebsiella Pneumoniae Infection Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Klebsiella Pneumoniae Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Klebsiella Pneumoniae Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Klebsiella Pneumoniae Infection Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Klebsiella Pneumoniae Infection Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Klebsiella Pneumoniae Infection Drug industry.

Chapter 3: Detailed analysis of Klebsiella Pneumoniae Infection Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Klebsiella Pneumoniae Infection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Klebsiella Pneumoniae Infection Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Klebsiella Pneumoniae Infection Drug Industry Trends Table 2. Klebsiella Pneumoniae Infection Drug Industry Drivers Table 3. Klebsiella Pneumoniae Infection Drug Industry Opportunities and Challenges Table 4. Klebsiella Pneumoniae Infection Drug Industry Restraints Table 5. Global Klebsiella Pneumoniae Infection Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Klebsiella Pneumoniae Infection Drug Revenue Share by Company (2021-2026) Table 7. Global Klebsiella Pneumoniae Infection Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Klebsiella Pneumoniae Infection Drug Sales Volume Share by Company (2021-2026) Table 9. Global Klebsiella Pneumoniae Infection Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Klebsiella Pneumoniae Infection Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Klebsiella Pneumoniae Infection Drug Key Company Manufacturing Base & Headquarters Table 12. Global Klebsiella Pneumoniae Infection Drug Company, Product Type & Application Table 13. Global Klebsiella Pneumoniae Infection Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Klebsiella Pneumoniae Infection Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of ATI-1503 Table 18. Significant Companies of CA-824 Table 19. Significant Companies of CC-1807 Table 20. Significant Companies of Cefiderocol Table 21. Significant Companies of Debio-1454 Table 22. Significant Companies of EBX-004 Table 23. Significant Companies of Others Table 24. Global Klebsiella Pneumoniae Infection Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Klebsiella Pneumoniae Infection Drug Sales Volume by Type (2021-2026) & (k units) Table 26. Global Klebsiella Pneumoniae Infection Drug Sales Volume by Type (2027-2032) & (k units) Table 27. Global Klebsiella Pneumoniae Infection Drug Sales Volume Share by Type (2021-2026) Table 28. Global Klebsiella Pneumoniae Infection Drug Sales Volume Share by Type (2027-2032) Table 29. Global Klebsiella Pneumoniae Infection Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Klebsiella Pneumoniae Infection Drug Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Klebsiella Pneumoniae Infection Drug Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Klebsiella Pneumoniae Infection Drug Sales Value Share by Type (2021-2026) Table 33. Global Klebsiella Pneumoniae Infection Drug Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Hospital Table 35. Significant Companies of Clinic Table 36. Significant Companies of Others Table 37. Global Klebsiella Pneumoniae Infection Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Klebsiella Pneumoniae Infection Drug Sales Volume by Application (2021-2026) & (k units) Table 39. Global Klebsiella Pneumoniae Infection Drug Sales Volume by Application (2027-2032) & (k units) Table 40. Global Klebsiella Pneumoniae Infection Drug Sales Volume Share by Application (2021-2026) Table 41. Global Klebsiella Pneumoniae Infection Drug Sales Volume Share by Application (2027-2032) Table 42. Global Klebsiella Pneumoniae Infection Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Klebsiella Pneumoniae Infection Drug Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Klebsiella Pneumoniae Infection Drug Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Klebsiella Pneumoniae Infection Drug Sales Value Share by Application (2021-2026) Table 46. Global Klebsiella Pneumoniae Infection Drug Sales Value Share by Application (2027-2032) Table 47. Global Klebsiella Pneumoniae Infection Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 48. Global Klebsiella Pneumoniae Infection Drug Sales by Region (2021-2026) & (k units) Table 49. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Region (2021-2026) Table 50. Global Klebsiella Pneumoniae Infection Drug Sales by Region (2027-2032) & (k units) Table 51. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Region (2027-2032) Table 52. Global Klebsiella Pneumoniae Infection Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Klebsiella Pneumoniae Infection Drug Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Klebsiella Pneumoniae Infection Drug Sales Value Share by Region (2021-2026) Table 55. Global Klebsiella Pneumoniae Infection Drug Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Klebsiella Pneumoniae Infection Drug Sales Value Share by Region (2027-2032) Table 57. Global Klebsiella Pneumoniae Infection Drug Market Average Price (US$/unit) by Region (2021-2026) Table 58. Global Klebsiella Pneumoniae Infection Drug Market Average Price (US$/unit) by Region (2027-2032) Table 59. Global Klebsiella Pneumoniae Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 60. Global Klebsiella Pneumoniae Infection Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 62. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2026) Table 63. Global Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032) & (k units) Table 64. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2027-2032) Table 65. Global Klebsiella Pneumoniae Infection Drug Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Klebsiella Pneumoniae Infection Drug Sales Value Market Share by Country (2021-2026) Table 67. Global Klebsiella Pneumoniae Infection Drug Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Klebsiella Pneumoniae Infection Drug Sales Value Market Share by Country (2027-2032) Table 69. Acies Bio doo Company Information Table 70. Acies Bio doo Business Overview Table 71. Acies Bio doo Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Acies Bio doo Klebsiella Pneumoniae Infection Drug Product Portfolio Table 73. Acies Bio doo Recent Development Table 74. Appili Therapeutics Company Information Table 75. Appili Therapeutics Business Overview Table 76. Appili Therapeutics Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Appili Therapeutics Klebsiella Pneumoniae Infection Drug Product Portfolio Table 78. Appili Therapeutics Recent Development Table 79. Debiopharm International SA Company Information Table 80. Debiopharm International SA Business Overview Table 81. Debiopharm International SA Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Debiopharm International SA Klebsiella Pneumoniae Infection Drug Product Portfolio Table 83. Debiopharm International SA Recent Development Table 84. Evaxion Biotech ApS Company Information Table 85. Evaxion Biotech ApS Business Overview Table 86. Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Product Portfolio Table 88. Evaxion Biotech ApS Recent Development Table 89. FOB Synthesis Inc Company Information Table 90. FOB Synthesis Inc Business Overview Table 91. FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 93. FOB Synthesis Inc Recent Development Table 94. ImmunoClin Corp Company Information Table 95. ImmunoClin Corp Business Overview Table 96. ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Product Portfolio Table 98. ImmunoClin Corp Recent Development Table 99. Innovation Pharmaceuticals Inc Company Information Table 100. Innovation Pharmaceuticals Inc Business Overview Table 101. Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 103. Innovation Pharmaceuticals Inc Recent Development Table 104. Kyorin Pharmaceutical Co Ltd Company Information Table 105. Kyorin Pharmaceutical Co Ltd Business Overview Table 106. Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 108. Kyorin Pharmaceutical Co Ltd Recent Development Table 109. Melinta Therapeutics Inc Company Information Table 110. Melinta Therapeutics Inc Business Overview Table 111. Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 113. Melinta Therapeutics Inc Recent Development Table 114. Nosopharm SAS Company Information Table 115. Nosopharm SAS Business Overview Table 116. Nosopharm SAS Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Nosopharm SAS Klebsiella Pneumoniae Infection Drug Product Portfolio Table 118. Nosopharm SAS Recent Development Table 119. Peptilogics Inc Company Information Table 120. Peptilogics Inc Business Overview Table 121. Peptilogics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Peptilogics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 123. Peptilogics Inc Recent Development Table 124. Phico Therapeutics Ltd Company Information Table 125. Phico Therapeutics Ltd Business Overview Table 126. Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 128. Phico Therapeutics Ltd Recent Development Table 129. Sarepta Therapeutics Inc Company Information Table 130. Sarepta Therapeutics Inc Business Overview Table 131. Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 133. Sarepta Therapeutics Inc Recent Development Table 134. Shionogi & Co Ltd Company Information Table 135. Shionogi & Co Ltd Business Overview Table 136. Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 138. Shionogi & Co Ltd Recent Development Table 139. Syntiron LLC Company Information Table 140. Syntiron LLC Business Overview Table 141. Syntiron LLC Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Syntiron LLC Klebsiella Pneumoniae Infection Drug Product Portfolio Table 143. Syntiron LLC Recent Development Table 144. Tetraphase Pharmaceuticals Inc Company Information Table 145. Tetraphase Pharmaceuticals Inc Business Overview Table 146. Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 148. Tetraphase Pharmaceuticals Inc Recent Development Table 149. Pfizer Inc Company Information Table 150. Pfizer Inc Business Overview Table 151. Pfizer Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 152. Pfizer Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 153. Pfizer Inc Recent Development Table 154. F. Hoffmann-La Roche Ltd Company Information Table 155. F. Hoffmann-La Roche Ltd Business Overview Table 156. F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 157. F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 158. F. Hoffmann-La Roche Ltd Recent Development Table 159. Key Raw Materials Table 160. Raw Materials Key Suppliers Table 161. Klebsiella Pneumoniae Infection Drug Distributors List Table 162. Klebsiella Pneumoniae Infection Drug Customers List Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources Table 166. Primary Sources List of Figures Figure 1. Klebsiella Pneumoniae Infection Drug Product Image Figure 2. Global Klebsiella Pneumoniae Infection Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Klebsiella Pneumoniae Infection Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Klebsiella Pneumoniae Infection Drug Sales (2021-2032) & (k units) Figure 5. Global Klebsiella Pneumoniae Infection Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Klebsiella Pneumoniae Infection Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. ATI-1503 Image Figure 10. CA-824 Image Figure 11. CC-1807 Image Figure 12. Cefiderocol Image Figure 13. Debio-1454 Image Figure 14. EBX-004 Image Figure 15. Others Image Figure 16. Global Klebsiella Pneumoniae Infection Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Klebsiella Pneumoniae Infection Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Klebsiella Pneumoniae Infection Drug Sales Volume Share by Type (2021-2032) Figure 19. Global Klebsiella Pneumoniae Infection Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Klebsiella Pneumoniae Infection Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Klebsiella Pneumoniae Infection Drug Sales Value Share by Type (2021-2032) Figure 22. Hospital Image Figure 23. Clinic Image Figure 24. Others Image Figure 25. Global Klebsiella Pneumoniae Infection Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Klebsiella Pneumoniae Infection Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Klebsiella Pneumoniae Infection Drug Sales Volume Share by Application (2021-2032) Figure 28. Global Klebsiella Pneumoniae Infection Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Klebsiella Pneumoniae Infection Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Klebsiella Pneumoniae Infection Drug Sales Value Share by Application (2021-2032) Figure 31. Global Klebsiella Pneumoniae Infection Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 32. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Klebsiella Pneumoniae Infection Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Klebsiella Pneumoniae Infection Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Klebsiella Pneumoniae Infection Drug Sales Value (2021-2032) & (US$ Million) Figure 36. North America Klebsiella Pneumoniae Infection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Klebsiella Pneumoniae Infection Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Klebsiella Pneumoniae Infection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Klebsiella Pneumoniae Infection Drug Sales Value (2021-2032) & (US$ Million) Figure 42. South America Klebsiella Pneumoniae Infection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Klebsiella Pneumoniae Infection Drug Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Klebsiella Pneumoniae Infection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Klebsiella Pneumoniae Infection Drug Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Klebsiella Pneumoniae Infection Drug Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • ATI-1503
  • CA-824
  • CC-1807
  • Cefiderocol
  • Debio-1454
  • EBX-004
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Acies Bio doo
  • Appili Therapeutics
  • Debiopharm International SA
  • Evaxion Biotech ApS
  • FOB Synthesis Inc
  • ImmunoClin Corp
  • Innovation Pharmaceuticals Inc
  • Kyorin Pharmaceutical Co Ltd
  • Melinta Therapeutics Inc
  • Nosopharm SAS
  • Peptilogics Inc
  • Phico Therapeutics Ltd
  • Sarepta Therapeutics Inc
  • Shionogi & Co Ltd
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Klebsiella Pneumoniae Infection Drug Sales Value (2021-2032)
  4. 1.2.2 Global Klebsiella Pneumoniae Infection Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Klebsiella Pneumoniae Infection Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Klebsiella Pneumoniae Infection Drug Market Dynamics
  1. 2.1 Klebsiella Pneumoniae Infection Drug Industry Trends
  2. 2.2 Klebsiella Pneumoniae Infection Drug Industry Drivers
  3. 2.3 Klebsiella Pneumoniae Infection Drug Industry Opportunities and Challenges
  4. 2.4 Klebsiella Pneumoniae Infection Drug Industry Restraints
3 Klebsiella Pneumoniae Infection Drug Market by Company
  1. 3.1 Global Klebsiella Pneumoniae Infection Drug Company Revenue Ranking in 2025
  2. 3.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Company (2021-2026)
  3. 3.3 Global Klebsiella Pneumoniae Infection Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Klebsiella Pneumoniae Infection Drug Average Price by Company (2021-2026)
  5. 3.5 Global Klebsiella Pneumoniae Infection Drug Company Ranking (2024-2026)
  6. 3.6 Global Klebsiella Pneumoniae Infection Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Klebsiella Pneumoniae Infection Drug Company Product Type and Application
  8. 3.8 Global Klebsiella Pneumoniae Infection Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Klebsiella Pneumoniae Infection Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Klebsiella Pneumoniae Infection Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Klebsiella Pneumoniae Infection Drug Market by Type
  1. 4.1 Klebsiella Pneumoniae Infection Drug Type Introduction
  2. 4.1.1 ATI-1503
  3. 4.1.2 CA-824
  4. 4.1.3 CC-1807
  5. 4.1.4 Cefiderocol
  6. 4.1.5 Debio-1454
  7. 4.1.6 EBX-004
  8. 4.1.7 Others
  9. 4.2 Global Klebsiella Pneumoniae Infection Drug Sales Volume by Type
  10. 4.2.1 Global Klebsiella Pneumoniae Infection Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Klebsiella Pneumoniae Infection Drug Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Klebsiella Pneumoniae Infection Drug Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Klebsiella Pneumoniae Infection Drug Sales Value by Type
  14. 4.3.1 Global Klebsiella Pneumoniae Infection Drug Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Klebsiella Pneumoniae Infection Drug Sales Value by Type (2021-2032)
  16. 4.3.3 Global Klebsiella Pneumoniae Infection Drug Sales Value Share by Type (2021-2032)
5 Klebsiella Pneumoniae Infection Drug Market by Application
  1. 5.1 Klebsiella Pneumoniae Infection Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Klebsiella Pneumoniae Infection Drug Sales Volume by Application
  6. 5.2.1 Global Klebsiella Pneumoniae Infection Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Klebsiella Pneumoniae Infection Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Klebsiella Pneumoniae Infection Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Klebsiella Pneumoniae Infection Drug Sales Value by Application
  10. 5.3.1 Global Klebsiella Pneumoniae Infection Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Klebsiella Pneumoniae Infection Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Klebsiella Pneumoniae Infection Drug Sales Value Share by Application (2021-2032)
6 Klebsiella Pneumoniae Infection Drug Regional Sales and Value Analysis
  1. 6.1 Global Klebsiella Pneumoniae Infection Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Klebsiella Pneumoniae Infection Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Klebsiella Pneumoniae Infection Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Klebsiella Pneumoniae Infection Drug Sales by Region (2027-2032)
  5. 6.3 Global Klebsiella Pneumoniae Infection Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Klebsiella Pneumoniae Infection Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Klebsiella Pneumoniae Infection Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Klebsiella Pneumoniae Infection Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Klebsiella Pneumoniae Infection Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Klebsiella Pneumoniae Infection Drug Sales Value (2021-2032)
  12. 6.6.2 North America Klebsiella Pneumoniae Infection Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Klebsiella Pneumoniae Infection Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Klebsiella Pneumoniae Infection Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Klebsiella Pneumoniae Infection Drug Sales Value (2021-2032)
  21. 6.9.2 South America Klebsiella Pneumoniae Infection Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Klebsiella Pneumoniae Infection Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Klebsiella Pneumoniae Infection Drug Sales Value Share by Country, 2025 VS 2032
7 Klebsiella Pneumoniae Infection Drug Country-level Sales and Value Analysis
  1. 7.1 Global Klebsiella Pneumoniae Infection Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Klebsiella Pneumoniae Infection Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032)
  6. 7.4 Global Klebsiella Pneumoniae Infection Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Klebsiella Pneumoniae Infection Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Klebsiella Pneumoniae Infection Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Acies Bio doo
  2. 8.1.1 Acies Bio doo Company Information
  3. 8.1.2 Acies Bio doo Business Overview
  4. 8.1.3 Acies Bio doo Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Acies Bio doo Klebsiella Pneumoniae Infection Drug Product Portfolio
  6. 8.1.5 Acies Bio doo Recent Developments
  7. 8.2 Appili Therapeutics
  8. 8.2.1 Appili Therapeutics Company Information
  9. 8.2.2 Appili Therapeutics Business Overview
  10. 8.2.3 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Product Portfolio
  12. 8.2.5 Appili Therapeutics Recent Developments
  13. 8.3 Debiopharm International SA
  14. 8.3.1 Debiopharm International SA Company Information
  15. 8.3.2 Debiopharm International SA Business Overview
  16. 8.3.3 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Product Portfolio
  18. 8.3.5 Debiopharm International SA Recent Developments
  19. 8.4 Evaxion Biotech ApS
  20. 8.4.1 Evaxion Biotech ApS Company Information
  21. 8.4.2 Evaxion Biotech ApS Business Overview
  22. 8.4.3 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Product Portfolio
  24. 8.4.5 Evaxion Biotech ApS Recent Developments
  25. 8.5 FOB Synthesis Inc
  26. 8.5.1 FOB Synthesis Inc Company Information
  27. 8.5.2 FOB Synthesis Inc Business Overview
  28. 8.5.3 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  30. 8.5.5 FOB Synthesis Inc Recent Developments
  31. 8.6 ImmunoClin Corp
  32. 8.6.1 ImmunoClin Corp Company Information
  33. 8.6.2 ImmunoClin Corp Business Overview
  34. 8.6.3 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Product Portfolio
  36. 8.6.5 ImmunoClin Corp Recent Developments
  37. 8.7 Innovation Pharmaceuticals Inc
  38. 8.7.1 Innovation Pharmaceuticals Inc Company Information
  39. 8.7.2 Innovation Pharmaceuticals Inc Business Overview
  40. 8.7.3 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  42. 8.7.5 Innovation Pharmaceuticals Inc Recent Developments
  43. 8.8 Kyorin Pharmaceutical Co Ltd
  44. 8.8.1 Kyorin Pharmaceutical Co Ltd Company Information
  45. 8.8.2 Kyorin Pharmaceutical Co Ltd Business Overview
  46. 8.8.3 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  48. 8.8.5 Kyorin Pharmaceutical Co Ltd Recent Developments
  49. 8.9 Melinta Therapeutics Inc
  50. 8.9.1 Melinta Therapeutics Inc Company Information
  51. 8.9.2 Melinta Therapeutics Inc Business Overview
  52. 8.9.3 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  54. 8.9.5 Melinta Therapeutics Inc Recent Developments
  55. 8.10 Nosopharm SAS
  56. 8.10.1 Nosopharm SAS Company Information
  57. 8.10.2 Nosopharm SAS Business Overview
  58. 8.10.3 Nosopharm SAS Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Nosopharm SAS Klebsiella Pneumoniae Infection Drug Product Portfolio
  60. 8.10.5 Nosopharm SAS Recent Developments
  61. 8.11 Peptilogics Inc
  62. 8.11.1 Peptilogics Inc Company Information
  63. 8.11.2 Peptilogics Inc Business Overview
  64. 8.11.3 Peptilogics Inc Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Peptilogics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  66. 8.11.5 Peptilogics Inc Recent Developments
  67. 8.12 Phico Therapeutics Ltd
  68. 8.12.1 Phico Therapeutics Ltd Company Information
  69. 8.12.2 Phico Therapeutics Ltd Business Overview
  70. 8.12.3 Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  72. 8.12.5 Phico Therapeutics Ltd Recent Developments
  73. 8.13 Sarepta Therapeutics Inc
  74. 8.13.1 Sarepta Therapeutics Inc Company Information
  75. 8.13.2 Sarepta Therapeutics Inc Business Overview
  76. 8.13.3 Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  78. 8.13.5 Sarepta Therapeutics Inc Recent Developments
  79. 8.14 Shionogi & Co Ltd
  80. 8.14.1 Shionogi & Co Ltd Company Information
  81. 8.14.2 Shionogi & Co Ltd Business Overview
  82. 8.14.3 Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  84. 8.14.5 Shionogi & Co Ltd Recent Developments
  85. 8.15 Syntiron LLC
  86. 8.15.1 Syntiron LLC Company Information
  87. 8.15.2 Syntiron LLC Business Overview
  88. 8.15.3 Syntiron LLC Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Syntiron LLC Klebsiella Pneumoniae Infection Drug Product Portfolio
  90. 8.15.5 Syntiron LLC Recent Developments
  91. 8.16 Tetraphase Pharmaceuticals Inc
  92. 8.16.1 Tetraphase Pharmaceuticals Inc Company Information
  93. 8.16.2 Tetraphase Pharmaceuticals Inc Business Overview
  94. 8.16.3 Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  96. 8.16.5 Tetraphase Pharmaceuticals Inc Recent Developments
  97. 8.17 Pfizer Inc
  98. 8.17.1 Pfizer Inc Company Information
  99. 8.17.2 Pfizer Inc Business Overview
  100. 8.17.3 Pfizer Inc Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Pfizer Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  102. 8.17.5 Pfizer Inc Recent Developments
  103. 8.18 F. Hoffmann-La Roche Ltd
  104. 8.18.1 F. Hoffmann-La Roche Ltd Company Information
  105. 8.18.2 F. Hoffmann-La Roche Ltd Business Overview
  106. 8.18.3 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  108. 8.18.5 F. Hoffmann-La Roche Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Klebsiella Pneumoniae Infection Drug Value Chain Analysis
  2. 9.1.1 Klebsiella Pneumoniae Infection Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Klebsiella Pneumoniae Infection Drug Sales Mode & Process
  6. 9.2 Klebsiella Pneumoniae Infection Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Klebsiella Pneumoniae Infection Drug Distributors
  9. 9.2.3 Klebsiella Pneumoniae Infection Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst